• Trevor Perrior, CEO, Domainex
    Our medicinal chemists believe that 'every compound counts' - Dr Trevor Perrior, CEO
    Every Compound Counts
  • Domainex is committed to the support of exciting and cutting-edge translational research
    Domainex is committed to the support of exciting and cutting-edge translational research
    Translational Research
  • Domainex applies unique technologies to overcome common drug discovery challenges
    Domainex applies unique technologies to overcome common drug discovery challenges
    Overcome Challenges
  • Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Exciting Pipeline

Drug Discovery Services

Domainex is the fastest growing CRO in Europe.  By applying our novel proprietary technologies such as CDH and taking a focussed, integrated approach to medicinal chemistry, biochemistry and computational chemistry we can reduce your project timeline by up to 30%.
 

Read more

New technologies

Domainex has launched its new PoLiPa technology, which can purify any GPCR without the need for thermostabilising mutations or detergents by encapsulating it in a polymer along with a small disc of the native cell membrane lipids. PoLiPa-GPCRs are pharmacologically intact and very stable.

Read more

Technology

FragmentBuilder logo
FragmentBuilder:
Fragment screening using MicroScale Thermophoresis


Combinatorial Domain Hunting logo
Combinatorial Domain Hunting
: Protein expression and purification services.


BioassayBuilder logo
BioassayBuilder
: Bioassay services, assay development, HTS and compound testing services.


LeadBuilder logo
LeadBuilder
: Virtual hit screening platform.

Events

24th February to 25th February 2020
Cambridge, UK
13th April to 17th April 2020
San Diego, USA